Search Results - "Adelman, DC"

Open‐label follow‐on study evaluating the efficacy, safety, and quality of life with extended daily oral immunotherapy in children with peanut allergy by Fernandez‐Rivas, Montserrat, Vereda, Andrea, Vickery, Brian P., Sharma, Vibha, Nilsson, Caroline, Muraro, Antonella, Hourihane, Jonathan O'B., DunnGalvin, Audrey, Toit, George, Blumchen, Katharina, Beyer, Kirsten, Smith, Alex, Ryan, Robert, Adelman, Daniel C., Jones, Stacie M.

“…Background The benefit of daily administration of Peanut (Arachis hypogaea) Allergen Powder‐dnfp (PTAH)—formerly AR101—has been established in clinical trials,…”
Get full text

Imipenem cross-reactivity with penicillin in humans by Saxon, A, Adelman, D C, Patel, A, Hajdu, R, Calandra, G B

“…We examined the potential for IgE-mediated cross-reactivity between the carbepenems, a new class of beta-lactam antibiotics, represented by imipenem, and…”
Get more information

Onset of eosinophilic esophagitis during a clinical trial program of oral immunotherapy for peanut allergy by Nilsson, Caroline, Scurlock, Amy M., Dellon, Evan S., Brostoff, Joshua M., Pham, Trinh, Ryan, Robert, Brown, Kari R., Adelman, Daniel C., Aceves, Seema S.

“…In this analysis of the PTAH clinical trial program, the overall incidence of EoE was approximately 1%, which is lower than previously reported rates of EoE…”
Get full text

Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer by GORDON, M. S, MARGOLIN, K, TALPAZ, M, SLEDGE, G. W, HOLMGREN, E, BENJAMIN, R, STALTER, S, SHAK, S, ADELMAN, D. C

“…We investigated the safety and pharmacokinetics of a recombinant human monoclonal antibody to vascular endothelial growth factor (rhuMAb VEGF) in patients with…”
Get full text

Continuous and Daily Oral Immunotherapy for Peanut Allergy: Results from a 2-Year Open-Label Follow-On Study (vol 9, pg 1879, 2021) by Vickery, BP, Vereda, A, Nilsson, C, du Toit, G, Shref, WG, Burks, AW, Jones, SM, Fernandez-Rivas, M, Blumchen, K, Hourihane, JO, Beyer, K, Anagnostou, A, Assa'ad, AH, Ben-Shoshan, M, Bird, JA, Carr, TF, Ciaccio, W, Casale, TB, Chong, HJ, Ciaccio, CE, Dorsey, MJ, Fineman, SM, Fritz, SB, Greiner, AN, Greos, LS, Hampel, FC, Ibanez, MD, Jeong, DK, Johnston, DT, Kachru, R, Kim, EH, Lanser, BJ, Leonard, SA, Maier, MC, Mans, LE, Muraro, A, Ohayon, JA, Elberink, JNGO, Petroni, DH, Pongracic, JA, Portnoy, JM, Rachid, R, Rupp, NT, Sanders, GM, Sharma, HP, Sharma, V, Sher, ER, Sher, L, Sindher, SB, Siri, D, Spergel, JM, Sprikkelman, AB, Sussman, GL, Tsoumani, M, Varshney, P, Vitalpur, G, Wang, JL, Yang, WLH, Zubeldia, JM, Smith, A, Ryan, R, Adelman, DC

Get full text

PALISADE follow-on study (ARC004): Longer-term outcomes with AR101 oral immunotherapy for peanut allergy by Fernandez-Rivas, M, Hourihane, JO, Blumchen, K, Jones, SM, Shreffler, WG, Du Toit, G, Muraro, A, Beyer, K, Sprikkelman, A, Smith, A, Vickery, BP, Adelman, DC, Nilsson, C

Get full text

Down-regulation of Fc epsilon RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody by MacGlashan, DW Jr, Bochner, B S, Adelman, D C, Jardieu, P M, Togias, A, McKenzie-White, J, Sterbinsky, SA, Hamilton, R G, Lichtenstein, L M

“…Treatment of allergic disease by decreasing circulating IgE with anti-IgE Abs is currently under clinical study. Based on previous unrelated studies, it…”
Get full text

Treatment satisfaction with AR101 oral immunotherapy for peanut allergy in a European paediatric population by Sharma, V, Du Toit, G, Fernandez-Rivas, M, Beyer, K, Turner, PJ, Blumchen, K, Nilsson, C, Ibanez, MD, Deschildre, A, Muraro, A, Erlewyn-Lajeunesse, M, Zubeldia, JM, De Blay, F, Sauvage, CD, Byrne, A, Chapman, J, Boralevi, F, Norval, D, Adelman, DC, Hourihane, JO

Get full text

Down-regulation of human basophil IgE and FC epsilon RI alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo by Saini, S S, MacGlashan, Jr, D W, Sterbinsky, S A, Togias, A, Adelman, D C, Lichtenstein, L M, Bochner, B S

“…Previously, infusions of an anti-IgE mAb (rhumAb-E25) in subjects decreased serum IgE levels, basophil IgE and FcepsilonRIalpha surface density, and polyclonal…”
Get full text

Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis by Casale, Thomas B., Bernstein, I.Leonard, Busse, William W., LaForce, Craig F., Tinkelman, David G., Stoltz, Randall R., Dockhorn, Robert J., Reimann, James, Su, John Q., Fick, Robert B., Adelman, Daniel C.

“…Background: Increased serum levels of antigen-specific IgE are often associated with allergic respiratory disorders. RhuMAb-E25, a recombinant humanized…”
Get full text

Phase I drug and light dose-escalation trial of motexafin lutetium and far red light activation (phototherapy) in subjects with coronary artery disease undergoing percutaneous coronary intervention and stent deployment: Procedural and long-term results by KEREIAKES, Dean J, SZYNISZEWSKI, Arthur M, CHOU, Tony M, POPMA, Jeffrey, FITZGERALD, Peter, CARROLL, Tanya E, FORER, David, ADELMAN, Daniel C, WAHR, Dennis, HERRMANN, Howard C, SIMON, Daniel I, ROGERS, Campbell, KRAMER, Paul, SHEAR, Wendy, YEUNG, Alan C, SHUNK, Kendrick A

“…Motexafin lutetium (MLu; Antrin) is a photosensitizer that is taken up by atherosclerotic plaque and concentrated within macrophages and vascular smooth muscle…”
Get full text

Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects by FAHY, J. V, COCKCROFT, D. W, BOULET, L.-P, WONG, H. H, DESCHESNES, F, DAVIS, E. E, RUPPEL, J, SU, J. Q, ADELMAN, D. C

“…Intravenous administration of a humanized monoclonal antibody of IgE (E25) attenuates the early and late phase response to inhaled allergen in allergic…”
Get full text

Photoangioplasty for human peripheral atherosclerosis: Results of a phase I trial of photodynamic therapy with motexafin lutetium (Antrin) by ROCKSON, Stanley G, KRAMER, Paul, ADELMAN, Daniel C, RAZAVI, Mahmood, SZUBA, Andrzej, FILARDO, Steven, FITZGERALD, Peter, COOKE, John P, YOUSUF, Shuja, DEVAULT, Arthur R, RENSCHLER, Markus F

“…In photoangioplasty, light activation of a photosensitive drug offers the potential for treatment of long segments of vascular disease. This is a brief…”
Get full text

Photodynamic Therapy With Motexafin Lutetium Induces Redox-Sensitive Apoptosis of Vascular Cells by Chen, Zhiping, Woodburn, Kathryn W, Shi, Can, Adelman, Daniel C, Rogers, Campbell, Simon, Daniel I

“…ABSTRACT—Motexafin lutetium is a photosensitizer that accumulates in atherosclerotic plaque and, after activation by far-red light, produces cytotoxic singlet…”
Get full text

Photodynamic therapy: Applications in atherosclerotic vascular disease with motexafin lutetium by Chou, Tony M., Woodburn, Kathryn W., Cheong, Wai-Fung, Lacy, Steven A., Sudhir, Krishnankutty, Adelman, Daniel C., Wahr, Dennis

“…Photodynamic therapy (PDT) has been approved as a tissue‐specific light‐activated cytotoxic therapy for many diseases. The ability of PDT to destroy target…”
Get full text

Immediate hypersensitivity reactions to beta-lactam antibiotics by Saxon, A, Beall, G N, Rohr, A S, Adelman, D C

“…Allergic reactions to the beta-lactam antibiotics (penicillins, cephalosporins, carbapenems, and monobactams) are a major factor limiting their use. Immediate…”
Get more information

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of High-Dose Intravenous Immunoglobulin for Oral Corticosteroid-Dependent Asthma by Kishiyama, J.L., Valacer, D., Cunningham-Rundles, C., Sperber, K., Richmond, G.W., Abramson, S., Glovsky, M., Stiehm, R., Stocks, J., Rosenberg, L., Shames, R.S., Corn, B., Shearer, W.T., Bacot, B., DiMaio, M., Tonetta, S., Adelman, D.C.

“…To determine the efficacy of high doses of intravenous gammaglobulin (IVIG) for the treatment of severe, steroid-dependent asthma in patients between 6 and 68…”
Get full text

Clinical differences among women with and without self-reported perimenstrual asthma by Shames, R S, Heilbron, D C, Janson, S L, Kishiyama, J L, Au, D S, Adelman, D C

“…Studies suggesting that 30% to 40% of asthmatic women report significant perimenstrual (late luteal phase) exacerbations of asthma are primarily retrospective,…”
Get more information

Serum IgE level drives basophil and mast cell IgE receptor display by MacGlashan, Jr, D W, Bochner, B S, Adelman, D C, Jardieu, P M, Togias, A, Lichtenstein, L M

Get more information

The cross-reactivity and immunology of β-lactam antibiotics by KISHIYAMA, J. L, ADELMAN, D. C

“…Allergic reactions to beta-lactam antibiotics are well described; however, only the immunochemistry of penicillin has been characterised. Although the major…”
Get full text